Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial.

@article{Heijde2012TimingAM,
  title={Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial.},
  author={D{\'e}sir{\'e}e Mfm van der Heijde and Edward Clark Keystone and Jeffrey R. Curtis and Robert B. M. Landew{\'e} and Michael H. Schiff and Dinesh Khanna and Tore Kristian Kvien and Lucian M. Ionescu and Leon M Gervitz and Owen R Davies and Kristel Luijtens and Daniel e. Furst},
  journal={The Journal of rheumatology},
  year={2012},
  volume={39 7},
  pages={1326-33}
}
OBJECTIVE To determine the relationship between timing and magnitude of Disease Activity Score [DAS28(ESR)] nonresponse (DAS28 improvement thresholds not reached) during the first 12 weeks of treatment with certolizumab pegol (CZP) plus methotrexate, and the likelihood of achieving low disease activity (LDA) at 1 year in patients with rheumatoid arthritis. METHODS In a post-hoc analysis of the RAPID 1 study, patients achieving LDA [DAS28(ESR) ≤ 3.2] at Year 1 were assessed according to DAS28… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

Similar Papers

Loading similar papers…